CVE-2003-1387

Public Exploit

Description

Buffer overflow in Opera 6.05 and 6.06, and possibly other versions, allows remote attackers to execute arbitrary code via a URL with a long username.

Category

7.5
CVSS
Severity: High
CVSS 2.0 •
EPSS 9.98% Top 10%
Third-Party Advisory securityreason.com Third-Party Advisory securityfocus.com Third-Party Advisory securityfocus.com Third-Party Advisory securityfocus.com Third-Party Advisory ibmcloud.com
Affected: n/a n/a
Published at:
Updated at:

References

Link Tags
http://www.securityfocus.com/archive/1/315794 mailing list exploit vdb entry third party advisory broken link
http://www.securityfocus.com/archive/1/311194 mailing list vdb entry third party advisory broken link
http://www.securityfocus.com/bid/6811 patch vdb entry third party advisory broken link
http://securityreason.com/securityalert/3253 third party advisory broken link
https://exchange.xforce.ibmcloud.com/vulnerabilities/11281 vdb entry third party advisory

Frequently Asked Questions

What is the severity of CVE-2003-1387?
CVE-2003-1387 has been scored as a high severity vulnerability.
How to fix CVE-2003-1387?
To fix CVE-2003-1387, make sure you are using an up-to-date version of the affected component(s) by checking the vendor release notes. As for now, there are no other specific guidelines available.
Is CVE-2003-1387 being actively exploited in the wild?
It is possible that CVE-2003-1387 is being exploited or will be exploited in a near future based on public information. According to its EPSS score, there is a ~10% probability that this vulnerability will be exploited by malicious actors in the next 30 days.
This platform uses data from the NIST NVD, MITRE CVE, MITRE CWE, First.org and CISA KEV but is not endorsed or certified by these entities. CVE is a registred trademark of the MITRE Corporation and the authoritative source of CVE content is MITRE's CVE web site. CWE is a registred trademark of the MITRE Corporation and the authoritative source of CWE content is MITRE's CWE web site.
© 2025 Under My Watch. All Rights Reserved.